Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Pembrolizumab at Usual or Low Dose in Non-squamous Lung Cancer (PULSE)
2021-006795-16Phase 3Active
- Sponsor
- Gustave Roussy
- Start
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Gustave Roussy. Primary endpoint: Overall survival. Started Jul 2022; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-006795-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006795-16.